Therapy of sickle cell disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Patients suffering from Sickle Cell Disease (SCD) are constantly exposed to a variety of health hazards, particularly infections and acute crises: a regular surveillance of their clinical and haematological situation is therefore necessary. As for preventive measures, penicillin protection is usually effective to reduce the frequency of infection, together with vaccination against common pathogens. Blood transfusions are given to prevent cerebral vascular accidents. Among pharmacological agents so far tested, a prominent role is played by compounds which have been proven capable to reactivate the production of Foetal Haemoglobin (HbF), as the presence of significant amounts of this haemoglobin can reduce the incidence and severity of complications; to this aim the best compound available at present is hydroxycarbamide (HC), or hydroxyurea, which has demonstrated a beneficial effect on both clinical and blood parameters of SCD patients: this has been very recently linked with a direct action on erythroid genes, like BCL11A, which are involved in the regulation of HbF levels. Histone deacetylase inhibitors, like butyrate, are also under investigation; vaso-dilators like nitric oxide, failed to give consistent results in recent trials. Pain management includes opiate analgesics, corticosteroids and oxygen administration. Transfusion therapy is mainly indicated for acute events, but regular transfusions are given to high-risk children for stroke prevention. Red cell exchange has the edge over simple blood transfusions when a fast reduction of HbS amount is required, namely in the presence of neurological symptoms. In patients receiving chronic transfusion regimens iron chelation treatment is necessary to avoid iron overload. Haemopoietic stem cell transplantation (HST) is the only curative treatment, but is possible only in a limited number of cases. The most promising option is gene therapy, particularly after the introduction of induced pluripotent stem cells (iPS), which appear an appropriate target for permanent integration of a therapeutic transgene: experiments are under way to obtain genetic correction of SCD haemopoiesis as well as β-thalassemia. The insertion of an ankirin insulator into a lentiviral vector is part of the new approaches for the treatment of these disorders.

Original languageEnglish
Title of host publicationSickle Cell Disease: A New Vision for an Old Problem
PublisherNova Science Publishers, Inc.
Pages173-186
Number of pages14
ISBN (Print)9781622574698
Publication statusPublished - 2013

Fingerprint

Sickle Cell Anemia
Blood Transfusion
Opiate Alkaloids
Therapeutics
Induced Pluripotent Stem Cells
Fetal Hemoglobin
Histone Deacetylase Inhibitors
Iron Overload
Thalassemia
Hydroxyurea
Butyrates
Stem Cell Transplantation
Pain Management
Infection
Transgenes
Penicillins
Genetic Therapy
Accidents
Blood Vessels
Analgesics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Eridani, S., Graziadei, G., Marcon, A., & Cappellini, M. D. (2013). Therapy of sickle cell disease. In Sickle Cell Disease: A New Vision for an Old Problem (pp. 173-186). Nova Science Publishers, Inc..

Therapy of sickle cell disease. / Eridani, S.; Graziadei, G.; Marcon, A.; Cappellini, M. D.

Sickle Cell Disease: A New Vision for an Old Problem. Nova Science Publishers, Inc., 2013. p. 173-186.

Research output: Chapter in Book/Report/Conference proceedingChapter

Eridani, S, Graziadei, G, Marcon, A & Cappellini, MD 2013, Therapy of sickle cell disease. in Sickle Cell Disease: A New Vision for an Old Problem. Nova Science Publishers, Inc., pp. 173-186.
Eridani S, Graziadei G, Marcon A, Cappellini MD. Therapy of sickle cell disease. In Sickle Cell Disease: A New Vision for an Old Problem. Nova Science Publishers, Inc. 2013. p. 173-186
Eridani, S. ; Graziadei, G. ; Marcon, A. ; Cappellini, M. D. / Therapy of sickle cell disease. Sickle Cell Disease: A New Vision for an Old Problem. Nova Science Publishers, Inc., 2013. pp. 173-186
@inbook{11f7dd86d76d48b6b558ba06318aa33a,
title = "Therapy of sickle cell disease",
abstract = "Patients suffering from Sickle Cell Disease (SCD) are constantly exposed to a variety of health hazards, particularly infections and acute crises: a regular surveillance of their clinical and haematological situation is therefore necessary. As for preventive measures, penicillin protection is usually effective to reduce the frequency of infection, together with vaccination against common pathogens. Blood transfusions are given to prevent cerebral vascular accidents. Among pharmacological agents so far tested, a prominent role is played by compounds which have been proven capable to reactivate the production of Foetal Haemoglobin (HbF), as the presence of significant amounts of this haemoglobin can reduce the incidence and severity of complications; to this aim the best compound available at present is hydroxycarbamide (HC), or hydroxyurea, which has demonstrated a beneficial effect on both clinical and blood parameters of SCD patients: this has been very recently linked with a direct action on erythroid genes, like BCL11A, which are involved in the regulation of HbF levels. Histone deacetylase inhibitors, like butyrate, are also under investigation; vaso-dilators like nitric oxide, failed to give consistent results in recent trials. Pain management includes opiate analgesics, corticosteroids and oxygen administration. Transfusion therapy is mainly indicated for acute events, but regular transfusions are given to high-risk children for stroke prevention. Red cell exchange has the edge over simple blood transfusions when a fast reduction of HbS amount is required, namely in the presence of neurological symptoms. In patients receiving chronic transfusion regimens iron chelation treatment is necessary to avoid iron overload. Haemopoietic stem cell transplantation (HST) is the only curative treatment, but is possible only in a limited number of cases. The most promising option is gene therapy, particularly after the introduction of induced pluripotent stem cells (iPS), which appear an appropriate target for permanent integration of a therapeutic transgene: experiments are under way to obtain genetic correction of SCD haemopoiesis as well as β-thalassemia. The insertion of an ankirin insulator into a lentiviral vector is part of the new approaches for the treatment of these disorders.",
author = "S. Eridani and G. Graziadei and A. Marcon and Cappellini, {M. D.}",
year = "2013",
language = "English",
isbn = "9781622574698",
pages = "173--186",
booktitle = "Sickle Cell Disease: A New Vision for an Old Problem",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Therapy of sickle cell disease

AU - Eridani, S.

AU - Graziadei, G.

AU - Marcon, A.

AU - Cappellini, M. D.

PY - 2013

Y1 - 2013

N2 - Patients suffering from Sickle Cell Disease (SCD) are constantly exposed to a variety of health hazards, particularly infections and acute crises: a regular surveillance of their clinical and haematological situation is therefore necessary. As for preventive measures, penicillin protection is usually effective to reduce the frequency of infection, together with vaccination against common pathogens. Blood transfusions are given to prevent cerebral vascular accidents. Among pharmacological agents so far tested, a prominent role is played by compounds which have been proven capable to reactivate the production of Foetal Haemoglobin (HbF), as the presence of significant amounts of this haemoglobin can reduce the incidence and severity of complications; to this aim the best compound available at present is hydroxycarbamide (HC), or hydroxyurea, which has demonstrated a beneficial effect on both clinical and blood parameters of SCD patients: this has been very recently linked with a direct action on erythroid genes, like BCL11A, which are involved in the regulation of HbF levels. Histone deacetylase inhibitors, like butyrate, are also under investigation; vaso-dilators like nitric oxide, failed to give consistent results in recent trials. Pain management includes opiate analgesics, corticosteroids and oxygen administration. Transfusion therapy is mainly indicated for acute events, but regular transfusions are given to high-risk children for stroke prevention. Red cell exchange has the edge over simple blood transfusions when a fast reduction of HbS amount is required, namely in the presence of neurological symptoms. In patients receiving chronic transfusion regimens iron chelation treatment is necessary to avoid iron overload. Haemopoietic stem cell transplantation (HST) is the only curative treatment, but is possible only in a limited number of cases. The most promising option is gene therapy, particularly after the introduction of induced pluripotent stem cells (iPS), which appear an appropriate target for permanent integration of a therapeutic transgene: experiments are under way to obtain genetic correction of SCD haemopoiesis as well as β-thalassemia. The insertion of an ankirin insulator into a lentiviral vector is part of the new approaches for the treatment of these disorders.

AB - Patients suffering from Sickle Cell Disease (SCD) are constantly exposed to a variety of health hazards, particularly infections and acute crises: a regular surveillance of their clinical and haematological situation is therefore necessary. As for preventive measures, penicillin protection is usually effective to reduce the frequency of infection, together with vaccination against common pathogens. Blood transfusions are given to prevent cerebral vascular accidents. Among pharmacological agents so far tested, a prominent role is played by compounds which have been proven capable to reactivate the production of Foetal Haemoglobin (HbF), as the presence of significant amounts of this haemoglobin can reduce the incidence and severity of complications; to this aim the best compound available at present is hydroxycarbamide (HC), or hydroxyurea, which has demonstrated a beneficial effect on both clinical and blood parameters of SCD patients: this has been very recently linked with a direct action on erythroid genes, like BCL11A, which are involved in the regulation of HbF levels. Histone deacetylase inhibitors, like butyrate, are also under investigation; vaso-dilators like nitric oxide, failed to give consistent results in recent trials. Pain management includes opiate analgesics, corticosteroids and oxygen administration. Transfusion therapy is mainly indicated for acute events, but regular transfusions are given to high-risk children for stroke prevention. Red cell exchange has the edge over simple blood transfusions when a fast reduction of HbS amount is required, namely in the presence of neurological symptoms. In patients receiving chronic transfusion regimens iron chelation treatment is necessary to avoid iron overload. Haemopoietic stem cell transplantation (HST) is the only curative treatment, but is possible only in a limited number of cases. The most promising option is gene therapy, particularly after the introduction of induced pluripotent stem cells (iPS), which appear an appropriate target for permanent integration of a therapeutic transgene: experiments are under way to obtain genetic correction of SCD haemopoiesis as well as β-thalassemia. The insertion of an ankirin insulator into a lentiviral vector is part of the new approaches for the treatment of these disorders.

UR - http://www.scopus.com/inward/record.url?scp=84892096030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892096030&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892096030

SN - 9781622574698

SP - 173

EP - 186

BT - Sickle Cell Disease: A New Vision for an Old Problem

PB - Nova Science Publishers, Inc.

ER -